CINACALCET TARO 90 MG

国: イスラエル

言語: 英語

ソース: Ministry of Health

有効成分:

CINACALCET AS HYDROCHLORIDE

から入手可能:

TARO INTERNATIONAL LTD, ISRAEL

ATCコード:

H05BX01

医薬品形態:

FILM COATED TABLETS

構図:

CINACALCET AS HYDROCHLORIDE 90 MG

投与経路:

PER OS

処方タイプ:

Required

製:

SYNTHON B.V., NETHERLANDS

治療領域:

CINACALCET

適応症:

Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet Taro may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

承認日:

2023-10-31

情報リーフレット

This Patient leaflet was formatted according to Ministry of Health
guidelines. It was
reviewed and approved by the Ministry of Health in November 2018
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) -
1986
The dispensing of this medicine requires a doctor's prescription
CINACALCET TARO FILM-COATED TABLETS 30 MG, 60 MG, 90 MG
ACTIVE INGREDIENT AND ITS QUANTITY
Each film-coated tablet contains 30 mg, 60 mg or 90 mg of cinacalcet
(as
hydrochloride).
INACTIVE INGREDIENTS AND ALLERGENS: SEE SECTION 6 'ADDITIONAL
INFORMATION'.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet
contains essential information about the medicine. If you have any
further questions,
consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It
may harm them, even if it seems to you that their illness is similar
to yours.
THIS MEDICINE IS NOT FOR USE IN CHILDREN AND ADOLESCENTS UNDER 18
YEARS OF AGE.
1. WHAT IS THIS MEDICINE INTENDED FOR?
Cinacalcet Taro is used:

to treat secondary hyperparathyroidism in patients with serious kidney
disease
who need dialysis to clear their blood of waste products.

to reduce high levels of calcium in the blood (hypercalcemia) in
patients with
parathyroid cancer.

to reduce high levels of calcium in the blood (hypercalcemia) in
patients with
primary hyperparathyroidism when removal of the gland is not possible.
THERAPEUTIC GROUP: Cinacalcet Taro is a calcimimetic agent.
Cinacalcet Taro works by controlling the levels of parathyroid hormone
(PTH),
calcium, and phosphorous in your body. It is used to treat problems
with organs
called parathyroid glands. The parathyroids are four small glands in
the neck, near
the thyroid gland, that produce parathyroid hormone (PTH).
In primary and secondary hyperparathyroidism too much PTH is produced
by the
parathyroid glands. 'Primary' means that the hyperparathyroidism is
not caused by
any other condition and 'secondary' means that the hyp